Abstract
Since the discovery of the PRLs in the 1990s, a large body of work has established that PRL overexpression endows cells with malignant properties and in human cancers is associated with disease progression and poor outcome. How the PRLs exert these effects at the molecular level remains unknown despite an intensive search for PRL substrates, including amongst components of key cancer-associated receptor-proximal signaling pathways. We discuss evidence to support a developing theme that the main action of the PRLs is to alter programs of gene expression. By so doing, the PRLs drive changes in molecular networks and cellular architecture to transform cell properties and advance cancer. We propose that defining and functionally investigating the PRL “interactome” could inform the mechanistic basis of PRL actions by revealing effectors and targeting partners to facilitate substrate identification. We also highlight recent findings on the actions of the PRLs gained from the first few studies in whole animal models, on regulation of the PRLs, and on progress towards therapeutic targeting of PRL-overexpressing tumors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mohn KL, Laz TM, Hsu JC, Melby AE, Bravo R, et al. The immediate-early growth response in regenerating liver and insulin-stimulated H-35 cells: comparison with serum-stimulated 3T3 cells and identification of 41 novel immediate-early genes. Mol Cell Biol. 1991;11:381–90.
Diamond RH, Cressman DE, Laz TM, Abrams CS, Taub R. PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol Cell Biol. 1994;14:3752–62.
Montagna M, Serova O, Sylla BS, Feunteun J, Lenoir GM. A 100-kb physical and transcriptional map around the EDH17B2 gene: identification of three novel genes and a pseudogene of a human homologue of the rat PRL-1 tyrosine phosphatase. Hum Genet. 1995;96:532–8.
Cates CA, Michael RL, Stayrook KR, Harvey KA, Burke YD, et al. Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Lett. 1996;110:49–55.
Zeng Q, Hong W, Tan YH. Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun. 1998;244:421–7.
Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, et al. A phosphatase associated with metastasis of colorectal cancer. Science. 2001;294:1343–6.
Bessette DC, Qiu D, Pallen CJ. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev. 2008;27:231–52.
Guzinska-Ustymowicz K, Pryczynicz A. PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis. Anticancer Agents Med Chem. 2011;11:99–108.
Al-Aidaroos AQ, Zeng Q. PRL-3 phosphatase and cancer metastasis. J Cell Biochem. 2010;111:1087–98.
Rios P, Li X, Kohn M. Molecular mechanisms of the PRL phosphatases. FEBS J. 2013;280:505–24.
Liang F, Liang J, Wang WQ, Sun JP, Udho E, et al. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem. 2007;282:5413–9.
Zhang J, Xiao Z, Lai D, Sun J, He C, et al. miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer. Br J Cancer. 2012;107:352–9.
Wang H, Quah SY, Dong JM, Manser E, Tang JP, et al. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007;67:2922–6.
Dong Y, Zhang L, Zhang S, Bai Y, Chen H, et al. Phosphatase of regenerating liver 2 (PRL2) is essential for placental development by down-regulating PTEN (Phosphatase and Tensin Homologue Deleted on Chromosome 10) and activating Akt protein. J Biol Chem. 2012;287:32172–9.
Al-Aidaroos AQ, Yuen HF, Guo K, Zhang SD, Chung TH, et al. Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest. 2013;123:3459–71.
Liang F, Luo Y, Dong Y, Walls CD, Liang J, et al. Translational control of C-terminal Src kinase (Csk) expression by PRL3 phosphatase. J Biol Chem. 2008;283:10339–46.
Liu Y, Zhou J, Chen J, Gao W, Le Y, et al. PRL-3 promotes epithelial mesenchymal transition by regulating cadherin directly. Cancer Biol Ther. 2009;8:1352–9.
Liu H, Al-aidaroos AQ, Wang H, Guo K, Li J, et al. PRL-3 suppresses c-Fos and integrin alpha2 expression in ovarian cancer cells. BMC Cancer. 2013;13:80.
Nakashima M, Lazo JS. Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics. J Pharmacol Exp Ther. 2010;334:627–33.
Peng L, Xing X, Li W, Qu L, Meng L, et al. PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling. Mol Cancer. 2009;8:110.
Lee SK, Han YM, Yun J, Lee CW, Shin DS, et al. Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells. Int J Cancer. 2012;131:E190–203.
Lai W, Chen S, Wu H, Guan Y, Liu L, et al. PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCNN4 channels. Oncol Rep. 2011;26:909–17.
Ming J, Jiang Y, Jiang G, Zheng H. Phosphatase of regenerating liver-3 induces angiogenesis by increasing extracellular signal-regulated kinase phosphorylation in endometrial adenocarcinoma. Pathobiology. 2013;81:1–7.
Lian S, Meng L, Liu C, Xing X, Song Q, et al. PRL-3 activates NF-kappaB signaling pathway by interacting with RAP1. Biochem Biophys Res Commun. 2013;430:196–201.
Chu ZH, Liu L, Zheng CX, Lai W, Li SF, et al. Proteomic analysis identifies translationally controlled tumor protein as a mediator of phosphatase of regenerating liver-3-promoted proliferation, migration and invasion in human colon cancer cells. Chin Med J (Engl). 2011;124:3778–85.
Zheng P, Liu YX, Chen L, Liu XH, Xiao ZQ, et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res. 2010;9:4897–905.
Liu Y, Zheng P, Liu Y, Ji T, Liu X, et al. An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer. Gut. 2013;62:571–81.
Zhao Y, McIntosh KB, Rudra D, Schawalder S, Shore D, et al. Fine-structure analysis of ribosomal protein gene transcription. Mol Cell Biol. 2006;26:4853–62.
Platt JM, Ryvkin P, Wanat JJ, Donahue G, Ricketts MD, et al. Rap1 relocalization contributes to the chromatin-mediated gene expression profile and pace of cell senescence. Genes Dev. 2013;27:1406–20.
Dumaual CM, Steere BA, Walls CD, Wang M, Zhang ZY, et al. Integrated analysis of global mRNA and protein expression data in HEK293 cells overexpressing PRL-1. PLoS One. 2013;8:e72977.
Yu L, Kelly U, Ebright JN, Malek G, Saloupis P, et al. Oxidative stress-induced expression and modulation of Phosphatase of Regenerating Liver-1 (PRL-1) in mammalian retina. Biochim Biophys Acta. 2007;1773:1473–82.
Ishii T, Funato Y, Miki H. Thioredoxin-related protein 32 (TRP32) specifically reduces oxidized phosphatase of regenerating liver (PRL). J Biol Chem. 2013;288:7263–70.
Ribeiro N, Sousa SR, Brekken RA, Monteiro FJ. Role of SPARC in bone remodeling and cancer-related bone metastasis. J Cell Biochem. 2014;115(1):17–26.
Honore B, Baandrup U, Vorum H. Heterogeneous nuclear ribonucleoproteins F and H/H′ show differential expression in normal and selected cancer tissues. Exp Cell Res. 2004;294:199–209.
Dumaual CM, Sandusky GE, Soo HW, Werner SR, Crowell PL, et al. Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer. Am J Transl Res. 2012;4:83–101.
Ewing RM, Chu P, Elisma F, Li H, Taylor P, et al. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol. 2007;3:89.
Malik S, Roeder RG. Dynamic regulation of pol II transcription by the mammalian Mediator complex. Trends Biochem Sci. 2005;30:256–63.
Knuesel MT, Meyer KD, Donner AJ, Espinosa JM, Taatjes DJ. The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Mol Cell Biol. 2009;29:650–61.
Hardy S, Wong NN, Muller WJ, Park M, Tremblay ML. Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression. Cancer Res. 2010;70:8959–67.
Zimmerman MW, Homanics GE, Lazo JS. Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer. PLoS One. 2013;8:e58300.
Yan H, Kong D, Ge X, Gao X, Han X. Generation of conditional knockout alleles for PRL-3. J Biomed Res. 2011;25:438–43.
Pagarigan KT, Bunn BW, Goodchild J, Rahe TK, Weis JF, et al. Drosophila PRL-1 is a growth inhibitor that counteracts the function of the Src oncogene. PLoS One. 2013;8:e61084.
Nishimura A, Linder ME. Identification of a novel prenyl and palmitoyl modification at the CaaX motif of Cdc42 that regulates RhoGDI binding. Mol Cell Biol. 2013;33:1417–29.
Mijimolle N, Velasco J, Dubus P, Guerra C, Weinbaum CA, et al. Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell. 2005;7:313–24.
Park JE, Yuen HF, Zhou JB, Al-Aidaroos AQ, Guo K, et al. Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia. EMBO Mol Med. 2013;5:1351–66.
Leung AY, Man CH, Kwong YL. FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. Leukemia. 2013;27:260–8.
Zhou J, Bi C, Chng WJ, Cheong LL, Liu SC, et al. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS One. 2011;6:e19798.
Li Z, Cao Y, Jie Z, Liu Y, Li Y, et al. miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. Cancer Lett. 2012;323:41–7.
Zhou C, Liu G, Wang L, Lu Y, Yuan L, et al. MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1. PLoS One. 2013;8:e63142.
Wu ZS, Wu Q, Wang CQ, Wang XN, Wang Y, et al. MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer. 2010;10:542.
Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ, et al. Increased expression of PRL-1 protein correlates with shortened patient survival in human hepatocellular carcinoma. Clin Transl Oncol. 2012;14:287–93.
Matejuk A, Collet G, Nadim M, Grillon C, Kieda C. MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response. Arch Immunol Ther Exp (Warsz). 2013;61:285–99.
Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013;15:546–54.
Fiordalisi JJ, Dewar BJ, Graves LM, Madigan JP, Cox AD. Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion. PLoS One. 2013;8:e64309.
Kozlov G, Cheng J, Ziomek E, Banville D, Gehring K, et al. Structural insights into molecular function of the metastasis-associated phosphatase PRL-3. J Biol Chem. 2004;279:11882–9.
Sun JP, Wang WQ, Yang H, Liu S, Liang F, et al. Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion. Biochemistry. 2005;44:12009–21.
Andersen KM, Madsen L, Prag S, Johnsen AH, Semple CA, et al. Thioredoxin Txnl1/TRP32 is a redox-active cofactor of the 26 S proteasome. J Biol Chem. 2009;284:15246–54.
Zeng Q, Si X, Horstmann H, Xu Y, Hong W, et al. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J Biol Chem. 2000;275:21444–52.
Wang J, Kirby CE, Herbst R. The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. J Biol Chem. 2002;277:46659–68.
Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. 2008;111:806–15.
Krndija D, Munzberg C, Maass U, Hafner M, Adler G, et al. The phosphatase of regenerating liver 3 (PRL-3) promotes cell migration through Arf-activity-dependent stimulation of integrin alpha5 recycling. J Cell Sci. 2012;125:3883–92.
Honda A, Al-Awar OS, Hay JC, Donaldson JG. Targeting of Arf-1 to the early Golgi by membrin, an ER-Golgi SNARE. J Cell Biol. 2005;168:1039–51.
Guo K, Tang JP, Tan CP, Wang H, Zeng Q. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol Ther. 2008;7:750–7.
Guo K, Li J, Tang JP, Tan CP, Hong CW, et al. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med. 2011;3:99ra85.
Lv J, Liu C, Huang H, Meng L, Jiang B, et al. Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3. Gene Ther. 2013;20:834–45.
Peters CS, Liang X, Li S, Kannan S, Peng Y, et al. ATF-7, a novel bZIP protein, interacts with the PRL-1 protein-tyrosine phosphatase. J Biol Chem. 2001;276:13718–26.
Bai Y, Luo Y, Liu S, Zhang L, Shen K, et al. PRL-1 protein promotes ERK1/2 and RhoA protein activation through a non-canonical interaction with the Src homology 3 domain of p115 Rho GTPase-activating protein. J Biol Chem. 2011;286:42316–24.
Si X, Zeng Q, Ng CH, Hong W, Pallen CJ. Interaction of farnesylated PRL-2, a protein-tyrosine phosphatase, with the beta-subunit of geranylgeranyltransferase II. J Biol Chem. 2001;276:32875–82.
Forte E, Orsatti L, Talamo F, Barbato G, De Francesco R, et al. Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3. Biochim Biophys Acta. 2008;1783:334–44.
Choi MS, Min SH, Jung H, Lee JD, Lee TH, et al. The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability. Biochem Biophys Res Commun. 2011;406:305–9.
Peng L, Jin G, Wang L, Guo J, Meng L, et al. Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3. Biochem Biophys Res Commun. 2006;342:179–83.
Tian W, Qu L, Meng L, Liu C, Wu J, et al. Phosphatase of regenerating liver-3 directly interacts with integrin beta1 and regulates its phosphorylation at tyrosine 783. BMC Biochem. 2012;13:22.
Mizuuchi E, Semba S, Kodama Y, Yokozaki H. Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression. Int J Cancer. 2009;124:1802–10.
Semba S, Mizuuchi E, Yokozaki H. Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma. Cancer Sci. 2010;101:2254–61.
McParland V, Varsano G, Li X, Thornton J, Baby J, et al. The metastasis-promoting phosphatase PRL-3 shows activity toward phosphoinositides. Biochemistry. 2011;50:7579–90.
Peng Y, Du K, Ramirez S, Diamond RH, Taub R. Mitogenic up-regulation of the PRL-1 protein-tyrosine phosphatase gene by Egr-1. Egr-1 activation is an early event in liver regeneration. J Biol Chem. 1999;274:4513–20.
Xu J, Cao S, Wang L, Xu R, Chen G, et al. VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C. PLoS One. 2011;6:e27165.
Basak S, Jacobs SB, Krieg AJ, Pathak N, Zeng Q, et al. The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell. 2008;30:303–14.
Min SH, Kim DM, Heo YS, Kim YI, Kim HM, et al. New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53. Oncogene. 2009;28:545–54.
Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, et al. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem. 2002;277:43359–68.
Jiang Y, Liu XQ, Rajput A, Geng L, Ongchin M, et al. Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis. Cancer Res. 2011;71:234–44.
Zheng P, Meng HM, Gao WZ, Chen L, Liu XH, et al. Snail as a key regulator of PRL-3 gene in colorectal cancer. Cancer Biol Ther. 2011;12:742–9.
Wang H, Vardy LA, Tan CP, Loo JM, Guo K, et al. PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell. 2010;18:52–62.
Wang L, Shen Y, Song R, Sun Y, Xu J, et al. An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol Pharmacol. 2009;76:1238–45.
Sun ZH, Bu P. Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line. Exp Ther Med. 2012;3:1077–81.
Han YM, Lee SK, Jeong DG, Ryu SE, Han DC, et al. Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity. Bioorg Med Chem Lett. 2012;22:323–6.
Choi SK, Oh HM, Lee SK, Jeong DG, Ryu SE, et al. Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-3). Nat Prod Res. 2006;20:341–6.
Shin Y, Kim GD, Jeon JE, Shin J, Lee SK. Antimetastatic effect of halichondramide, a trisoxazole macrolide from the marine sponge Chondrosia corticata, on human prostate cancer cells via modulation of epithelial-to-mesenchymal transition. Mar Drugs. 2013;11:2472–85.
Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, et al. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther. 2002;1:1255–64.
Min G, Lee SK, Kim HN, Han YM, Lee RH, et al. Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells. Bioorg Med Chem Lett. 2013;23:3769–74.
Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, et al. Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer. BMC Cancer. 2011;11:122.
Ahn JH, Kim SJ, Park WS, Cho SY, Ha JD, et al. Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorg Med Chem Lett. 2006;16:2996–9.
Daouti S, Li WH, Qian H, Huang KS, Holmgren J, et al. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res. 2008;68:1162–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Rogers, C.A., Pallen, C.J. (2016). The PRL PTPs: Regulating Gene Expression to Reprogram the Cancer Cell. In: Neel, B., Tonks, N. (eds) Protein Tyrosine Phosphatases in Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3649-6_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3649-6_10
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-3647-2
Online ISBN: 978-1-4939-3649-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)